INmune Bio Achieves Commercial-Ready Manufacturing for CORDStrom, Paving Way for Global Filings
INMB sits 69% above its 52-week low of $1.09.
Summary
INmune Bio has successfully transferred its CORDStrom manufacturing process to a commercial-ready facility, a critical step toward planned Phase 3 trials and regulatory submissions in the US, EU, and UK. The milestone de-risks a major execution hurdle for cell therapy companies and supports the company's timeline for Ebstrocel™ in RDEB. This follows recent positive MHRA regulatory feedback and aligns with the UK's draft rare disease framework, strengthening the regulatory pathway. With a market cap around $50M and a going concern warning, operational progress like this is essential to maintaining momentum and attracting partnership or funding interest. The next catalyst will be the initiation of the Phase 3 confirmation trial and the MAA submission.
At the time of this announcement, INMB was trading at $1.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.5M. The 52-week trading range was $1.09 to $3.24. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.